The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 30 April 2004, www.theannals.com, DOI 10.1345/aph.1D302.
 The Annals of Pharmacotherapy: Vol. 38, No. 6, pp. 1006-1014. DOI 10.1345/aph.1D302
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Modrzejewski, K. A
Right arrow Articles by Herman, R. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Modrzejewski, K. A
Right arrow Articles by Herman, R. A

NEW DRUG APPROVALS

Emtricitabine: A Once-Daily Nucleoside Reverse Transcriptase Inhibitor

Krysten A Modrzejewski, PharmD

at time of writing, Drug Information Resident, Iowa Drug Information Service, University of Iowa Hospitals and Clinics, Iowa City, IA

Ronald A Herman, PhD

Director, Iowa Drug Information Network; Assistant Professor (Clinical), Iowa Drug Information Service, Iowa City

Reprints: Ronald A Herman PhD, Iowa Drug Information Network, 100 Oakdale Campus, N344 OH, Iowa City, IA 52242-5000, fax 319/335-4440, ronald-a-herman{at}uiowa.edu

OBJECTIVE: To review the pharmacology, virology, pharmacokinetics, safety, and efficacy of the nucleoside reverse transcriptase inhibitor (NRTI) emtricitabine.

DATA SOURCES: English-language reports were accessed using MEDLINE (1966–June 2003) and the Iowa Drug Information Service database (1966–June 2003) using emtricitabine and Coviracil as key words. (Coviracil was the proposed trade name for the product prior to approval.) The Internet was also searched using the terms HIV/AIDS conferences, then emtricitabine within the conference proceedings.

STUDY SELECTION AND DATA EXTRACTION: Abstracts, posters, and oral presentations from scientific conferences, both published and unpublished, were included. Preference was given to published controlled trials. Studies providing a description of the pharmacology, virology, effectiveness, safety, or pharmacokinetics of emtricitabine were used in this review.

DATA SYNTHESIS: Emtricitabine is an NRTI used to treat HIV-1 infection. Once-daily administration can decrease pill burden and potentially increase adherence to multidrug HIV therapy. Further, emtricitabine has shown equivalent or improved outcomes compared with lamivudine and stavudine.

CONCLUSIONS: Emtricitabine is a safe and effective option for HIV-1 infection in adults as part of a multidrug regimen. It may be a better alternative than lamivudine for once-daily therapy because of its extended intracellular half-life and better than lamivudine and stavudine because of a possibly decreased potential for drug resistance.

Key Words: antiretroviral therapy, emtricitabine, HIV, nucleoside reverse transcriptase inhibitor

Published Online, April 30, 2004. www.theannals.com, DOI 10.1345/aph.1D302

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-019-H02




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.